What were the primary drivers of the significant increase in net sales?

The primary driver for the substantial increase in net sales was the inclusion of revenue from the Cardiac Rhythm Management (CRM) and Cardiac Surgery divisions, which were acquired as part of the Guidant acquisition in April 2006.

Why did net income decrease so sharply despite higher sales?

The decrease in net income was due to several factors including acquisition-related charges, a significant increase in interest expense resulting from higher debt levels incurred to finance the Guidant acquisition, and an increase in operating expenses, particularly Selling, General, and Administrative (SG&A) expenses, as a percentage of net sales.

What is the outlook for the Coronary Stent business, especially regarding drug-eluting stents?

The Coronary Stent business faced challenges, with declining U.S. sales of the TAXUS stent due to a shrinking market size influenced by concerns over late stent thrombosis and lower drug-eluting stent penetration. Internationally, competitive new product launches also impacted market share. The company expects continued pressure on U.S. drug-eluting stent sales in the near term but is working on new product launches and regaining physician confidence.

What progress has been made regarding the FDA warning letter for the CRM business?

Boston Scientific received notification that the FDA has lifted the warning letter previously issued to Guidant's CRM facilities. This is considered a major milestone in the recovery of the CRM business, following reinspections where inspectors noted no observations, indicating progress in quality system improvements.

BSX 10-Q Quarterly Report Q1 FY2007 — Revenue, Net Income, EPS

Summary

Boston Scientific Corporation reported a significant increase in net sales for the first quarter of 2007, driven largely by the inclusion of Guidant's former businesses. While revenue grew by 29% to $2.086 billion compared to the prior year period, net income saw a substantial decrease to $120 million ($0.08 per diluted share) from $332 million ($0.40 per diluted share) in Q1 2006. This decline in profitability is attributed to acquisition-related charges, increased interest expense due to higher debt levels following the Guidant acquisition, and a higher operating expense ratio, particularly in selling, general, and administrative costs. Despite the reported net income decline, the company highlighted operational improvements, including the lifting of an FDA warning letter for its Cardiac Rhythm Management (CRM) facilities, which is seen as a key milestone for the CRM business. However, the coronary stent business faced headwinds, with declining sales due to concerns over late stent thrombosis and increased competition. Management is actively managing its debt and exploring strategic options like an Initial Public Offering for its Endosurgery group.

Key Highlights

1Net sales increased by 29% to $2.086 billion, primarily due to the inclusion of Guidant's businesses (CRM and Cardiac Surgery).
2Net income decreased significantly to $120 million ($0.08/share) from $332 million ($0.40/share) in the prior year quarter, impacted by acquisition-related costs and higher interest expenses.
3Gross profit margin declined by 4.1 percentage points year-over-year, influenced by product mix shifts and increased operating expenses.
4The company's Cardiac Rhythm Management (CRM) business is showing signs of recovery, highlighted by the FDA lifting its warning letter for Guidant's facilities.
5The Coronary Stent business experienced a decline in sales, impacted by decreased drug-eluting stent market penetration in the U.S. and increased competition internationally.
6Total debt remains high at $8.9 billion, though the company is focused on using operating cash flow to reduce it and is in compliance with its debt covenants.
7Boston Scientific is exploring an Initial Public Offering (IPO) for a minority interest in its Endosurgery group.

BOSTON SCIENTIFIC CORP Quarterly Report for Q1 Ended Mar 31, 2007

Summary

Key Highlights

Frequently Asked Questions